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Abstract
Objectives—We aimed to quantify the risk of major adverse cardiovascular events (MACE) 
among patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and psoriasis without 
known PsA compared to the general population after adjusting for traditional cardiovascular risk 
factors.
Methods—A population-based longitudinal cohort study from 1994–2010 was performed in The 
Health Improvement Network (THIN), a primary care medical record database in the United 
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Kingdom. Patients aged 18–89 with PsA, RA, or psoriasis were included. Up to 10 unexposed 
controls matched on practice and index date were selected for each patient with PsA. Outcomes 
included cardiovascular death, myocardial infarction, cerebrovascular accidents, and the 
composite outcome (MACE). Cox proportional hazards models were used to calculate the hazard 
ratios (HR) for each outcome adjusted for traditional risk factors. A priori we hypothesized an 
interaction between disease status and disease modifying anti-rheumatic drug (DMARD) use.
Results—Patients with PsA (N=8,706), RA (N=41,752), psoriasis (N=138,424) and unexposed 
controls (N=81,573) were identified. After adjustment for traditional risk factors, the risk of 
MACE was higher in PsA patients not prescribed a DMARD (HR 1.24, 95%CI: 1.03 to 1.49), 
patients with RA (No DMARD: HR 1.39, 95%CI: 1.28 to 1.50, DMARD: HR 1.58, 95%CI: 1.46 
to 1.70), patients with psoriasis not prescribed a DMARD (HR 1.08, 95%CI: 1.02 to 1.15) and 
patients with severe psoriasis (DMARD users: HR 1.42, 95%CI: 1.17 to 1.73).
Conclusions—Cardiovascular risk should be addressed with all patients affected by psoriasis, 
psoriatic arthritis or rheumatoid arthritis.
Keywords
Psoriatic Arthritis; Psoriasis; Rheumatoid Arthritis; Myocardial Infarction; Cerebrovascular Event; 
Cardiovascular Disease; stroke
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that occurs in approximately 8–
30% of patients with psoriasis. [1, 2] PsA has been linked to an increased prevalence of 
cardiovascular co-morbidities and cardiovascular risk factors. [3] However, the majority of 
studies performed to date have been cross-sectional. Cohort studies examining the risk of 
incident cardiovascular events in PsA are sparse. [4] Three population-based studies have 
examined the risk of cardiovascular events among patients with psoriasis and have included 
patients with PsA as a subgroup. [5–7] Existing studies have not examined the risk for 
incident major adverse cardiovascular events (MACE) including myocardial infarction (MI), 
cerebrovascular accidents (CVA), and cardiovascular death in PsA compared to matched 
internal controls from a population-based perspective after accounting for the presence of 
traditional cardiovascular risk factors.
Rheumatoid arthritis (RA) and severe psoriasis have been consistently linked to an increased 
risk for incident MACE. [3, 4, 8–16] It has been suggested that patients with PsA have a 
similarly elevated risk for cardiovascular disease. However, we recently demonstrated that 
patients with PsA did not have an increased risk of mortality compared to internal controls 
while patients with severe psoriasis (defined as psoriasis patients prescribed systemic 
therapy or phototherapy) and RA had substantially elevated mortality (HR 1.75 and 1.54–
1.59, respectively). [17] This led us to question whether PsA is associated with incident 
cardiovascular disease from a population-based perspective.
The objective of this study was to examine the risk of incident MACE including myocardial 
infarction (MI), cerebrovascular accidents (CVA), and cardiovascular death controlling for 
traditional cardiovascular risk factors among patients with psoriatic arthritis, rheumatoid 
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arthritis or psoriasis compared to unexposed controls using a population-based cohort. We 
hypothesized similar rates of cardiovascular disease among the three groups given known 
associations with systemic Th1- and Th17- driven inflammation. [18, 19]
METHODS
Study Design and Setting
A cohort study was performed using data from The Health Improvement Network (THIN) in 
the United Kingdom (UK) between 1994 and 2010. THIN is a large medical record database 
in which general practitioners (GP) record routine health data about their patients. [20–22] 
The UK is an ideal setting for examining long-term health outcomes given the gatekeeper 
model, meaning that GPs are responsible for coordinating all of the patient’s care. In 
addition, pay-for-performance measures mandate collection of data on cardiovascular 
outcomes and several key cardiovascular risk factors including diabetes and smoking. [23]
Study Population
All patients with PsA, psoriasis, or RA between the ages of 18 and 89 at the index date were 
included if they had observation time in THIN after Vision software implementation. 
Patients were excluded if they died or transferred out of the practice prior to the 
implementation of Vision software. Up to 10 unexposed controls from the general 
population without PsA, psoriasis, RA, or disease modifying anti-rheumatic drugs 
(DMARDs) prescriptions were randomly selected for each patient with PsA and were 
matched on practice and index date within the practice (defined as latest of registration with 
the practice and diagnosis date). Unexposed controls were assigned a “diagnosis date” 
within 6 months of the PsA patient’s diagnosis date. This algorithm was designed to 
minimize bias by ensuring that PsA and unexposed controls are followed by similar doctors 
during similar time periods. For each individual outcome analysis, patients were excluded if 
they had the outcome of interest prior to the index date.
Exposure Definitions
PsA, psoriasis, and RA were defined by the presence of at least one READ code consistent 
with these diseases (READ codes are standard medical diagnosis codes used in the UK 
general practice system) [24]. READ codes for psoriasis (positive predictive value [PPV] 
90%), [25] rheumatoid arthritis (PPV 81% for “potential cases” defined as single code 
without DMARD, rheumatoid factor result or rheumatology referral), [26–28] and PsA 
(PPV 85%) [2, 29] have been previously validated within the same or analogous large 
medical record databases. We have used this definition of PsA in other studies. [2, 17, 30, 
31] Patients were classified as PsA if they had a code for PsA, RA if they had a code for RA 
but not PsA, and psoriasis if they had a code for psoriasis but did not have a code for RA or 
PsA.
Outcome Definitions
Outcomes were defined by READ codes representing the outcome of interest within the 
study period. The censoring date was the first occurrence of the outcome of interest. Patients 
were excluded from each analysis if they had the event of interest prior to the index date. 
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Myocardial infarction and stroke were defined by a previously validated set of READ codes 
with PPV 93% [32] and 77.5–89.3% respectively. [33, 34] Cardiovascular (CV) death was 
defined by a set of READ codes chosen based on the UK ICD10 codes classifying a 
cardiovascular death and the Centers for Disease Control (CDC) ICD9 codes classifying 
death as heart disease or stroke. [35, 36] These codes were extracted within the 60 days prior 
or 180 days following a code signifying the patient's death. Text comments in the database 
reporting the patient's death as cardiovascular were also used to classify CV death. This 
algorithm has been used previously and is the recommended method for identifying cause of 
death by THIN. MACE, the composite outcome, was achieved at the first of MI, CVA, or 
cardiovascular death.
Person Time Calculation
The index date (cohort entry) was defined as the latest date of the following events: 
diagnosis date, six months after initial registration with the practice, DMARD initiation (in 
patients utilizing DMARDs), implementation of Vision software in the patient’s practice, or 
a practice acceptable mortality reporting. [37–40] The index data was similarly calculated in 
unexposed controls except for “diagnosis date” was the diagnosis date of the matched 
disease patient. Censoring occurred when the event of interest occurred, the patient died, the 
patient left the practice, the practice stopped participating in THIN, or the study ended in 
September 2010.
Covariates of Interest
All covariates of interest were measured prior to the index date. A priori, we hypothesized a 
statistical interaction between disease status and both age and DMARD use as disease 
severity may be reflected by DMARD use. DMARD exposure was included in the models as 
a binary variable for exposure at any point up to the index date. Among patients with RA 
and PsA, DMARDs included methotrexate, sulfasalazine, azathioprine, leflunamide, 
cyclosporine, mycophenolate, hydroxychloroquine, and biologic disease modifying agents 
including adalimumab, etanercept, and infliximab. In patients with skin psoriasis without a 
diagnosis of PsA or RA, methotrexate, cyclosporine, biologic disease modifying agents, 
phototherapy, psoralen (PUVA), retinoids (acitretin and etretinate), and hydroxyurea were 
considered DMARDs. In the United Kingdom, DMARDs can be prescribed by consultants 
(specialists) but should be captured by general practitioner records with the exception of the 
biologic medications, which are rarely recorded. [20] The following potential confounders 
were measured: age, sex, smoking, body mass index, blood pressure at baseline, year of 
cohort entry, Townsend deprivation score correlated with socioeconomic status [20]), urban 
versus rural living environment, chronic kidney disease, diabetes, hypertension, use of 
prescription non-steroidal anti-inflammatory drugs (NSAIDs) and oral corticosteroids prior 
to index date. The Charlson comorbidity score [41] was also calculated but the typical point 
for RA was not included in order to better capture differences in other comorbidities among 
the groups.
Statistical Analysis
Covariate distribution among the groups was examined using descriptive statistics. Cox 
proportional hazards regression models were used to calculate the hazard ratio (HR) for each 
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group compared to the unexposed group after adjusting for age and sex. Hypothesized effect 
modifiers, use of DMARDs and age, were tested in the models and the likelihood ratio test 
was used to determine significance of the interactions. We then tested the hypothesized 
confounders in the model using a purposeful selection modeling approach [42] and kept in 
the model the predetermined confounders (age, sex, and traditional cardiovascular risk 
factors) and covariates that changed the main effects by >10% and had a p-value<0.1. Log-
log survival plots and Schoenfeld residuals were used to assess the assumption of 
proportionality of hazards. Several sensitivity analyses were performed (more detail in 
Supplemental Figure 1). Statistical analysis was performed using Stata 13.0 (College 
Station, TX).
Sample Size Determination
Power calculations prior to the start of the study revealed that with 7,000 patients with PsA 
and 35,000 unexposed patients, we would have 90% power to detect a hazard ratio as small 
as 1.28, 1.16 and 1.19 for CV death, MI, and stroke, respectively, with an average of 5 years 
of follow-up per patient in an unadjusted analysis. Baseline event rates were assumed to be 
0.16%, 0.49%, and 0.35% per year for CV death, MI, and stroke, respectively.
Ethics Board Approval
All data in this study was anonymous to the investigators. This study was approved by the 
University of Pennsylvania Institutional Review Board and Cegedim’s Scientific Review 
Committee. This manuscript was prepared according to the STROBE statement 
recommendations. [43]
RESULTS
Among 8,706 patients with PsA, 41,752 patients with RA, 138,424 patients with psoriasis, 
and 82,258 randomly selected unexposed patients meeting the inclusion criteria, follow up 
time in the study period was comparable. Baseline characteristics are found in Table 1 
(additional patient characteristics are found in Supplemental Table 1). Patients with RA 
were older and more often female. Approximately half of patients with RA and PsA were 
prescribed a DMARD and 3% of patients with psoriasis had been prescribed a DMARD or 
received phototherapy. At least 65% of patients with PsA and RA had been prescribed 
NSAIDs compared to 24% with psoriasis and 47% of controls. Compared to the unexposed 
population, the prevalences of cardiovascular risk factors, MI and stroke in the baseline 
period were elevated in patients with PsA, RA and psoriasis. Reasons for leaving the cohort 
(censoring) other than having an outcome of interest were similar among groups (data not 
shown).
The unadjusted incidence rates of MI, CVA, and MACE (composite outcome) are reported 
in Table 2. Hazard ratios for myocardial infarction, stroke, cardiovascular death, and MACE 
are presented in Table 3. There was a significant interaction between DMARD status (ever 
vs never prescribed) and exposure (disease) group (p<0.001 for CV death, CVA, and MACE 
and p=0.01 for MI). Therefore, the stratified results are presented. The risk of any major 
adverse cardiovascular event (composite outcome) was elevated in patients with PsA 
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without a DMARD prescription (HR 1.24, 95% CI 1.03–1.49), RA (No DMARD: HR 1.39, 
95%CI 1.28–1.50 and DMARD user: 1.58, 95%CI 1.46–1.70) and severe psoriasis (defined 
as patients prescribed a DMARD; HR 1.42, 95%CI 1.17–1.73).
Patients with PsA had an elevated risk for incident MI (HR 1.36, 95%CI 1.04–1.77 and HR 
1.36, 95%CI 1.01 to 1.84 for no DMARD and DMARD respectively). The risk for MI was 
similarly elevated in patients with RA without a DMARD prescription (HR 1.33, 95%CI 
1.17–1.51) and patients with severe psoriasis (HR 1.26, 95%CI 0.92–1.72) but was 
substantially higher in patients with RA who had been prescribed a DMARD (HR 1.96, 
95%CI 1.75–2.19).
The risk of incident stroke was also significantly elevated in patients with PsA without a 
DMARD prescription (HR 1.33, 95%CI: 1.03–1.71) which was similar to patients with RA 
and severe psoriasis. Finally, cardiovascular death was only significantly elevated in RA 
(No DMARD: HR 1.43, 95%CI 1.28–1.59 and DMARD: HR 1.66, 95%CI 1.48–1.86) and 
severe psoriasis (HR 1.54, 95%CI 1.15–2.05).
A third interaction with age as a continuous variable was tested and found to be significant 
(p<0.001 for all four outcomes). The three way interactions are presented in Figure 1. The 
relative risk is highest in the younger age groups where the absolute risk is low. Few events 
occurred in patients younger than 50 years of age (13% of MI, 8% of stroke, 3% of CV 
death, and 10% of composite outcomes).
Our results were robust to several sensitivity analyses (Supplemental Figure 1) varying 
definitions of the outcomes, restricting to only patients followed regularly, utilizing multiple 
imputation for smoking and body mass index, and imputing additional DMARD users. 
However, in examining the role of death as a competing risk factor for cardiovascular 
events, all previously significant associations in PsA were null whereas the HR in the other 
groups remained unchanged. Finally, adjusting for potentially cardiovascular-protective 
medication use (e.g., antihypertensives, lipid lowering medications, and antiplatelet agents 
listed in Supplemental Table 1) during the one year prior to start date in the cohort and 
health care utilization in the baseline period (number of GP visits) did not significantly 
change the results. One such model is illustrated in Supplemental Table 2.
DISCUSSION
To our knowledge, this is the first population-based study dedicated to examining MACE in 
PsA which may be an independent risk factor for major cardiovascular events including 
myocardial infarction and stroke, although this was only statistically significant for patients 
who were not prescribed a DMARD. Additionally, this is the first longitudinal population-
based study dedicated to the simultaneous examination of the incidence of MACE in PsA, 
psoriasis and RA after adjusting for traditional cardiovascular risk factors. All three diseases 
had statistically similar risks for the development of incident cardiovascular events after 
adjustment for age, sex, calendar year of cohort entry, and traditional cardiovascular risk 
factors.
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Strengths of this study include the large cohort of patients, an average of 5 years of follow 
up, simultaneous comparison among three disease cohorts in a population-based study, and 
the use of THIN in which the exposures (psoriasis, RA, PsA) and outcomes (MI, CVA) have 
been validated. The incidences of MI and CVA in our unexposed population are similar to 
UK National Statistics [44], lending credence to our algorithms to identify these outcomes 
and the validity of our unexposed population. These statistics are based on inpatient 
hospitalizations but support our assumption that we have captured the majority of the 
outcomes of interest. Furthermore, the increased risk of cardiovascular disease in RA and 
psoriasis are similar to those reported in recent meta-analyses, lending internal validity to 
our results in PsA. [14, 16]
Our study has limitations including lack of disease activity measures in THIN, generally 
absent biologic medication records, possible missing DMARD prescriptions, and the 
inability to account for over-the-counter NSAID use. THIN does not include data on disease 
activity in psoriasis or inflammatory arthritis, limiting our ability to examine the effect of 
disease severity on the incidence of MACE. However, we have shown that simple GP 
categorization of body surface area affected by psoriasis is positively correlated with the 
prevalence of atherosclerotic disease in a prospective study we are conducting nested within 
the THIN population. [45] Use of a systemic DMARD or phototherapy in patients with 
psoriasis has previously been used as a proxy for severe psoriasis. [5, 10, 46] However, 
DMARDs are less likely to represent a pure marker of disease severity in patients with PsA 
or RA due to confounding by indication and a potential healthy user effect in patients with 
PsA (i.e., fewer comorbidities in PsA and psoriasis patients prescribed a DMARD). In 
contrast, patients with RA prescribed a DMARD could have had more events because their 
disease was more severe. However, we are unable to test this hypothesis. In patients with 
PsA who were prescribed a DMARD, the point estimates were nearly the same as patients 
without a DMARD prescription but the confidence interval crossed 1.0. This may be due to 
a lack of statistical power after stratification by DMARD status. It could also be the result of 
a healthy user effect, the anti-inflammatory effect of medications on atherosclerosis, or 
closer follow up in patients using DMARDs with more attention to cardiovascular risk 
reduction given more frequent physicians visits. [47, 48]
NSAIDs have been associated with the development of cardiovascular disease, [49] 
although this is less clear in patients with RA. [12] Over-the-counter NSAID use may be 
prevalent among our arthritis cohorts, particularly given that the majority of patients with 
arthritis have received a prescription NSAID. This should not substantially affect our results, 
however, as adjustment for prescription NSAID use did not change the main effects (results 
not shown). Similarly, GPs often do not record the use of biologic DMARDs as these are 
prescribed directly by rheumatology consultants in the hospital setting. [20] However, 
according to NICE guidelines in the UK, all patients must first fail at least one oral DMARD 
in order to receive a biologic DMARD prescription, [50] so these patients should have been 
captured in the "DMARD" group. However, in some cases, the rheumatology consultant will 
directly prescribe an oral DMARD and the GP may not record this. In a recent validation 
study, we examined the agreement between GP and medical record report of DMARD use 
and found that while agreement is overall good, 20 of 53 (38%) patients without a code for a 
DMARD were reported by the GP to have received a DMARD at some point. In the study, a 
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total of 51 of 87 patients (59%) had either a code for a DMARD or GP report of DMARD 
use. [29] Therefore, in a sensitivity analysis, we augmented the number of DMARD users by 
first deriving a propensity score (a treatment prediction model) and then assigning those in 
the top three quintiles a DMARD prescription; this did not change the results. Finally, there 
may be patients with PsA in the "psoriasis only" cohort who have not yet been diagnosed 
with inflammatory arthritis or whose diagnosis was not recorded. This concern is not unique 
to population-based studies but a general issue that makes comparison of cohorts of patients 
with psoriasis and PsA challenging. [51] The goal of this study was to examine PsA with 
high specificity and without physical examination or direct questioning of the patients; we 
did not seek to identify patients with subclinical or undiagnosed PsA.
In conclusion, we report an increased incidence of major adverse cardiovascular events in 
PsA, psoriasis and RA. The hazard ratios for RA and psoriasis were similar to risk estimates 
in previous studies providing internal validity for the study results in patients with PsA and 
external validity for the study as a whole. These results suggest the need for improved 
screening and management of traditional cardiovascular risk factors in patients with 
inflammatory diseases. Future prospective randomized controlled studies are needed to 
better understand the impact of systemic therapy in decreasing the risk of major adverse 
cardiovascular events in these diseases. Additionally, studies addressing the impact of 
interventions for traditional cardiovascular risk factors on reducing the risk for MACE in 
patients with inflammatory diseases are needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hazard Ratios by Age
These graphs incorporate the age interaction into the fully adjusted models for major adverse 
cardiovascular events, cardiovascular mortality, myocardial infarction, and stroke. The fully 
adjusted models include age, sex, hypertension, diabetes, hyperlipidemia, and smoking 
status (never, past, current).
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Table 3
Hazard Ratios and 95% Confidence Intervals for Major Adverse Cardiovascular Events
COMPOSITE OUTCOME
Unadjusted Age-Sex Adjusted Fully Adjusted*
Unexposed Ref Ref Ref
PsA No DMARD 1.34 (1.13–1.58) 1.33 (1.13–1.58) 1.24 (1.03–1.49)
DMARD 0.93 (0.76–1.13) 1.17 (.96–1.43) 1.17 (.95–1.46)
RA No DMARD 2.62 (2.44–2.81) 1.43 (1.33–1.53) 1.39 (1.28–1.50)
DMARD 2.17 (2.02–2.32) 1.62 (1.51–1.74) 1.58 (1.46–1.70)
Psoriasis No DMARD 1.07 (1.02–1.13) 1.16 (1.10–1.23) 1.08 (1.02–1.15)
DMARD 1.30 (1.08–1.57) 1.41 (1.17–1.71) 1.42 (1.17–1.73)
MYOCARDIAL INFARCTION
Unadjusted Age-Sex Adjusted Fully Adjusted
Unexposed Ref Ref Ref
PsA No DMARD 1.55 (1.21–1.98) 1.46 (1.14–1.86) 1.36 (1.04–1.77)
DMARD 1.19 (0.90–1.57) 1.35 (1.03–1.79) 1.36 (1.01–1.84)
RA No DMARD 2.20 (1.96–2.48) 1.36 (1.21–1.53) 1.33 (1.17–1.52)
DMARD 2.55 (2.30–2.83) 2.02 (1.82–2.24) 1.96 (1.75–2.19)
Psoriasis No DMARD 1.13 (1.04–1.23) 1.19 (1.09–1.29) 1.08 (.98–1.18)
DMARD 1.25 (.92–1.68) 1.30 (.96–1.76) 1.26 (.92–1.72)
STROKE
Unadjusted Age-Sex Adjusted Fully Adjusted
Unexposed Ref Ref Ref
PsA No DMARD 1.34 (1.05–1.69) 1.36 (1.08–1.73) 1.33 (1.03–1.71)
DMARD 0.85 (0.64–1.15) 1.12 (.83–1.50) 1.13 (.83–1.55)
RA No DMARD 2.54 (2.29–2.81) 1.29 (1.16–1.43) 1.29 (1.15–1.45)
DMARD 1.76 (1.59–1.96) 1.27 (1.14–1.41) 1.24 (1.10–1.39)
Psoriasis No DMARD 1.02 (0.95–1.11) 1.13 (1.05–1.22) 1.08 (.99–1.17)
DMARD 1.31 (1.00–1.71) 1.45 (1.11–1.90) 1.45 (1.10–1.92)
CARDIOVASCULAR DEATH
Unadjusted Age-Sex Adjusted Fully Adjusted
Unexposed Ref Ref Ref
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PsA No DMARD 1.16 (0.89–1.52) 1.30 (.99–1.70) 1.07 (.79–1.44)
DMARD 0.61 (0.42–0.88) .98 (.68–1.42) 0.96 (.64–1.43)
RA No DMARD 3.29 (2.97–3.63) 1.55 (1.40–1.71) 1.43 (1.28–1.59)
DMARD 2.18 (1.96–2.42) 1.69 (1.53–1.88) 1.66 (1.48–1.86)
Psoriasis No DMARD 1.07 (0.99–1.16) 1.22 (1.13–1.34) 1.09 (1.00–1.20)
DMARD 1.29 (0.97–1.71) 1.49 (1.12–1.98) 1.54 (1.15–2.05)
*
The fully adjusted models include age, sex, hypertension, diabetes, hyperlipidemia, smoking status (never, past, current), and start year in the 
cohort.
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